Search the MBS

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS), in a patient with:

(a)    advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or

(b)    triple negative early breast cancer; or

(c)    hormone receptor positive, HER2-negative, early breast cancer with one or more high-risk characteristics.

Applicable once per lifetime. 

Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,101.30

(See para PN.0.23 of explanatory notes to this Category)

• Previous - Item 73294
• Next - Item 73296